Johnson & Johnson Cash on Hand 2006-2020 | JNJ

Johnson & Johnson cash on hand from 2006 to 2020. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Johnson & Johnson cash on hand for the quarter ending March 31, 2020 was $18.024B, a 17.53% increase year-over-year.
  • Johnson & Johnson cash on hand for 2019 was $19.287B, a 2.03% decline from 2018.
  • Johnson & Johnson cash on hand for 2018 was $19.687B, a 7.6% increase from 2017.
  • Johnson & Johnson cash on hand for 2017 was $18.296B, a 56.34% decline from 2016.
Johnson & Johnson Annual Cash on Hand
(Millions of US $)
2019 $19,287
2018 $19,687
2017 $18,296
2016 $41,907
2015 $38,376
2014 $33,089
2013 $29,206
2012 $21,089
2011 $32,261
2010 $27,658
2009 $19,425
2008 $12,809
2007 $9,315
2006 $4,084
2005 $16,138
Johnson & Johnson Quarterly Cash on Hand
(Millions of US $)
2020-03-31 $18,024
2019-12-31 $19,287
2019-09-30 $17,945
2019-06-30 $15,278
2019-03-31 $15,336
2018-12-31 $19,687
2018-09-30 $19,364
2018-06-30 $18,139
2018-03-31 $15,204
2017-12-31 $18,296
2017-09-30 $16,231
2017-06-30 $12,853
2017-03-31 $39,343
2016-12-31 $41,907
2016-09-30 $40,433
2016-06-30 $42,584
2016-03-31 $39,855
2015-12-31 $38,376
2015-09-30 $37,306
2015-06-30 $33,954
2015-03-31 $31,319
2014-12-31 $33,089
2014-09-30 $33,005
2014-06-30 $31,624
2014-03-31 $29,392
2013-12-31 $29,206
2013-09-30 $25,228
2013-06-30 $25,129
2013-03-31 $21,668
2012-12-31 $21,089
2012-09-30 $19,771
2012-06-30 $16,915
2012-03-31 $33,847
2011-12-31 $32,261
2011-09-30 $30,927
2011-06-30 $29,682
2011-03-31 $26,867
2010-12-31 $27,658
2010-09-30 $22,126
2010-06-30 $18,901
2010-03-31 $18,010
2009-12-31 $19,425
2009-09-30 $14,337
2009-06-30 $14,716
2009-03-31 $13,933
2008-12-31 $12,809
2008-09-30 $14,799
2008-06-30 $13,058
2008-03-31 $11,144
2007-12-31 $9,315
2007-09-30 $8,320
2007-06-30 $5,971
2007-03-31 $5,191
2006-12-31 $4,084
2006-09-30 $14,692
2006-06-30 $14,725
2006-03-31 $17,185
2005-12-31 $16,138
2005-09-30 $15,179
2005-06-30 $13,161
2005-03-31 $13,650
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $371.399B $82.059B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Roche Holding AG (RHHBY) Switzerland $299.895B 0.00
Novartis AG (NVS) Switzerland $200.421B 15.66
Merck (MRK) United States $198.849B 14.40
Pfizer (PFE) United States $191.697B 11.90
Eli Lilly (LLY) United States $156.734B 25.37
Novo Nordisk (NVO) Denmark $156.265B 26.02
AbbVie (ABBV) United States $146.020B 10.73
AstraZeneca (AZN) United Kingdom $141.191B 29.08
Sanofi (SNY) $129.264B 14.96
GlaxoSmithKline (GSK) United Kingdom $103.401B 12.34
Bayer (BAYRY) Germany $70.202B 10.01
H Lundbeck (HLUYY) Denmark $7.753B 13.47
Innoviva (INVA) United States $1.417B 8.18